2Wan PT,Garnett MJ,Roe SM,et al.Mechanism of activation of the RAF-ERK signaling path way by oncogenic mutation of BRAF[J].Cell,2004,116(6):855-867.
3Xing M.BRAF mutaion in thyroid cancer[J].Endo cr Relat Cancer,2005,12(2):245-262.
4Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
5Beesley MF,Mclaren KM.Cytokeratin19 and galectin-3 imunohistochemistry in the differential diagnosis of solitary thyroid nodules[J].Histopathology,2002,41(3):236-243.
6Song Q,Wang D,Lou Y,et al.Diagnostic significance of CK19,TG,Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China[J].Diagn Pathol,2011,6:126.
7EI Demellawy D,Nasr A,Alowami S.Application of CD56,P63and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of thethyroid[J].Diagnosis Pathol,2008,3:5.
8Matesa-Ani D,Moslavac S,Matesa N,et al.Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms[J].Acta Clin Croat,2012,51(2):237-241.
9Ito Y,Yoshida H,Tomoda C,et al.Galectin-3 expression in follicular tumours:an immunohistochemical study of its use as a marker of follicular carcinoma[J].Pathology,2005,37(4):296-298.
10De Matos LL,Del Giglio AB,Matsubayashi CO,et al.Expression of CK-19,galectin-3 and HBME-1 in the differentiation of thyroid lesions:systematic review and diagnostic meta-analysis[J].Diagn Pathol,2012,13(7):97-103.
2Palazzo FF, Gosnell J, Savio R. Lymphadenectomy for papillarythyroid cancer: changes in practice over four decades[J]. Eur J Surg Oncol, 2006, 32(3):340-344.
3Sobin LH, Wittekind CH. TNM classification of malignant tumors[M]. 6th Edition. USA:Wiley-Liss, New York, 2002:52-56.
4Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification updates: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology- Head and Neck Surgery[J]. Arch Otolaryngol Head Neck Surg, 2002, 128(7):751-758.
5Guideline of thyroid cancer:in clinical practice guidelines in oncology,version 1, 2010, National Comprehensive Cancer Network (NCCN).
6Guidelines for the management of thyroid cancer in adults.2007. British Thyroid Association and Royal College of Physicians,London.
7Caron NR, Tan YY, Ogilivie JB, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?[J]. World J Surg, 2006, 30(5):833- 840.
8Kupferman ME, Weinstock YE, Santillan AA, et al. Predictors of level V metastasis in well-differentiated thyroid cancer[J].Head Neck, 2008, 30(11):1469-1474.
9Noguchi S, Clark OH, Noguchi S. thyroid cancer: diagnosis and treatment[M]. 1st edition, missouri: quality medical publishing, 2000:257-273.
